1
|
Slavotinek AM, Garcia ST, Chandratillake G, Bardakjian T, Ullah E, Wu D, Umeda K, Lao R, Tang PLF, Wan E, Madireddy L, Lyalina S, Mendelsohn BA, Dugan S, Tirch J, Tischler R, Harris J, Clark MJ, Chervitz S, Patwardhan A, West JM, Ursell P, de Alba Campomanes A, Schneider A, Kwok PY, Baranzini S, Chen RO. Exome sequencing in 32 patients with anophthalmia/microphthalmia and developmental eye defects. Clin Genet 2015; 88:468-73. [PMID: 25457163 DOI: 10.1111/cge.12543] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 11/09/2014] [Accepted: 11/19/2014] [Indexed: 12/17/2022]
Abstract
Anophthalmia/microphthalmia (A/M) is a genetically heterogeneous birth defect for which the etiology is unknown in more than 50% of patients. We used exome sequencing with the ACE Exome(TM) (Personalis, Inc; 18 cases) and UCSF Genomics Core (21 cases) to sequence 28 patients with A/M and four patients with varied developmental eye defects. In the 28 patients with A/M, we identified de novo mutations in three patients (OTX2, p.(Gln91His), RARB, p.Arg387Cys and GDF6, p.Ala249Glu) and inherited mutations in STRA6 in two patients. In patients with developmental eye defects, a female with cataracts and cardiomyopathy had a de novo COL4A1 mutation, p.(Gly773Arg), expanding the phenotype associated with COL4A1 to include cardiomyopathy. A male with a chorioretinal defect, microcephaly, seizures and sensorineural deafness had two PNPT1 mutations, p.(Ala507Ser) and c.401-1G>A, and we describe eye defects associated with this gene for the first time. Exome sequencing was efficient for identifying mutations in pathogenic genes for which there is no clinical testing available and for identifying cases that expand phenotypic spectra, such as the PNPT1 and COL4A1-associated disorders described here.
Collapse
Affiliation(s)
- A M Slavotinek
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.,Program in Human Genetics, University of California San Francisco, San Francisco, CA, USA
| | | | | | - T Bardakjian
- Division of Medical Genetics, Einstein Medical Center, Philadelphia, PA, USA
| | - E Ullah
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA.,Department of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan
| | - D Wu
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - K Umeda
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - R Lao
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA
| | - P L-F Tang
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA
| | - E Wan
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA
| | - L Madireddy
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - S Lyalina
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - B A Mendelsohn
- Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - S Dugan
- Division of Medical Genetics, Children's Hospitals & Clinics, Minneapolis, MN, USA
| | - J Tirch
- Personalis, Inc., Menlo Park, CA, USA
| | | | - J Harris
- Personalis, Inc., Menlo Park, CA, USA
| | - M J Clark
- Personalis, Inc., Menlo Park, CA, USA
| | | | | | - J M West
- Personalis, Inc., Menlo Park, CA, USA
| | - P Ursell
- Department of Pathology, University of California San Francisco, San Francisco, CA, USA
| | - A de Alba Campomanes
- Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA
| | - A Schneider
- Division of Medical Genetics, Einstein Medical Center, Philadelphia, PA, USA
| | - P-Y Kwok
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA
| | - S Baranzini
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - R O Chen
- Personalis, Inc., Menlo Park, CA, USA
| |
Collapse
|
2
|
Keefe DM, Garden A, Barasch A, Tischler R, Brennan M, Trotti A, Vera-Llonch M, Oster G, Elting L, Sonis S. Oral mucositis is associated with increased resource use among patients receiving treatment for cancers of the head and neck. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6070 Background: Oral mucositis (OM) is the oral manifestation of mucosal injury (MUI), and is a common, bothersome, and treatment-interrupting toxicity of chemoradiation therapy for squamous cell cancers (SCC) of the head and neck. Retrospective studies have reported that OM increases healthcare resource use. We present interim results of an international, multicenter, prospective study undertaken to characterize the clinical and economic burden of OM in patients with cancers of the oral cavity (OC), oropharynx (OP), larynx (L) and hypopharynx (HP). Methods: Patients (pts) with histologically proven SCC of the designated anatomical sites, whose planned treatment included full-cycle conventional or intensity modulated (IM) radiation therapy (RT) with or without chemotherapy, were enrolled at least one week prior to the start of treatment. Pts completed the Oral Mucositis Daily Questionnaire (OMDQ), a validated questionnaire developed to document patient-reported symptoms of OM and MUI including mouth and throat soreness (MTS), at baseline and daily throughout RT. MTS was assessed using a 5-point numeric rating scale, ranging from 0 (“no soreness”) to 4 (“extreme soreness”). Results: Of the first 61 pts to complete RT, 72% had cancers of the OC or OP, 49% received IMRT with concomitant chemotherapy, and 68% were male. 95% of pts reported OM symptoms (MTS>0); 80% had one or more scores =2. Pts with OC or OP cancers reported more symptoms than those with L or HP tumors (mean maximum score: 3.3 vs 2.8; p= 0.12). MTS scores were positively related to levels of resource use. Conclusions: Symptoms of radiation-induced OM are positively correlated with levels of resource utilization in patients with head and neck cancers. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- D. M. Keefe
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - A. Garden
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - A. Barasch
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - R. Tischler
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - M. Brennan
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - A. Trotti
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - M. Vera-Llonch
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - G. Oster
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - L. Elting
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| | - S. Sonis
- Royal Adelaide Hospital, Adelaide, Australia; MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Dana-Farber Cancer Institute, Boston, MA; Carolinas Medical Centre, Charlotte, NC; H. Lee Moffitt Cancer Center, Tampa, FL; Policy Analysis, inc, Boston, MA; Brigham and Women’s Hospital, Boston, MA
| |
Collapse
|